[Summary]
When investing in healthcare tech, it is not enough to look only at technological capabilities.
In the medical and nursing care business, depending on the system in each country, who pays the costs, whether prices can be determined freely, whether medical data can be used, and whether the shortage of nursing care personnel is compensated for by people or technology vary greatly.
In other words, differences in legal systems are not just a risk factor. It is a barrier to market entry, a rule that determines room for growth, and in some cases, it can be the very competitive advantage of a company. In medical DX and nursing care DX, companies that can create "sales that remain in the system" are stronger than good technology.
In this article, we will clarify the differences in public insurance, private insurance, insurance reimbursement, data regulations, and nursing care policies that are important when analyzing healthcare tech companies, and explain how to discern the growth potential of medical DX and nursing care DX stocks.
First, the conclusion
Healthcare tech is a "system industry."
Making investment decisions based solely on the words AI, DX, robots, and SaaS is a very dangerous area. This is because in the medical and nursing care fields, even if the service is good, it is difficult to generate sales unless it is included in the system.
There are three things investors should look at first:
| Axis to look at | Investor questions |
|---|---|
| Payer | Who pays the cost |
| Reimbursement/Subsidy | Will I be covered by insurance, medical fees, nursing care fees, and subsidies? |
| Data regulations | Is there a system in place to safely use medical and nursing care data |
Companies that have all three of these characteristics are not just theme stocks, but are more likely to generate recurring profits.
On the other hand, companies with fancy explanations of their technology, but with unclear payers, not being incorporated into the system, and weak evidence for data usage, tend to take a long time to sell.
Healthcare tech investment is “an investment that reads the system”
Healthcare tech is different from ordinary IT services.
With general SaaS, customer companies will implement it if they find it convenient. However, in the medical and nursing care fields, just because it is convenient in the field, it will not become widespread.
Implementation involves the operation of medical institutions, medical fees, nursing care fees, personal information protection, medical device regulations, local government budgets, subsidies, and insurance company payment rules.
Therefore, no matter how good the AI diagnostic support or nursing care robot is,
- Not covered by insurance
- Medical institutions cannot explain cost-effectiveness
- Increased on-site burden on nursing care facilities
- Weak personal information protection system
- Unable to drive on its own after subsidy ends
If so, growth will slow down.
Companies that benefit from the system are strong. If you can get into public insurance, private insurance, subsidies, local government introductions, and hospital group contracts, it will be easier for your sales to become recurring revenue rather than one-time revenue.
The most important point is “Who pays?”
The most important part of the healthcare business is the payer. This is called a payer.
Even for the same remote monitoring, the growth speed and profit margin will change depending on whether patients pay out of pocket, hospitals pay to improve operational efficiency, or insurance companies pay to reduce medical costs.
| Payer | Main regions/areas | Strengths | Risks |
|---|---|---|---|
| Public insurance | Japan, Europe, long-term care insurance market | Easily stable | Strong price controls |
| Private insurance | United States | Unit prices tend to be high | Difficult to obtain contracts |
| Medical institutions and nursing care facilities | Hospitals, facilities, and home care providers | Clear demand for operational efficiency | Limited implementation budget |
| Local government/national | Community medical care, nursing care prevention, and monitoring | Easy to follow policy themes | Easy to become dependent on subsidies |
| Individuals | Free medical treatment, prevention, wellness | Price flexibility | Affected by economic conditions and income differences |
Investors want to avoid services that have many users, but no one pays enough for.
In healthcare tech, social significance and profitability can sometimes be misaligned. That's why we need to see whose costs are lowered, whose revenues are increased, and whose budgets are paid for.
Japanese/European model | “Cost reduction model” is strong in the public insurance market
In Japan and Europe, public insurance systems are the center of medical and nursing care.
In this market, the prices of medical and nursing care services are controlled by a system. While it is difficult for companies to freely set high prices, once they are incorporated into the system, profits tend to be stable.
What is strong in the public insurance market is technology that lowers costs in government, medical and nursing care settings.
For example,
*AI interview
- Electronic medical record linkage
- Nursing care record DX
- Monitoring sensor
- Fall detection AI
- Medication management system
- Home medical monitoring
- Preventive medical data analysis
And so on.
These are more than just useful tools. It will be evaluated as infrastructure for filling the shortage of medical and nursing care workers and curbing the growth of social security costs.
In Japan, the Ministry of Health, Labor and Welfare is promoting medical DX, and electronic medical record information sharing and utilization of medical information are policy themes. Additionally, in the field of nursing care, support for the introduction of nursing care robots and ICT continues to be discussed.
The points investors should look at are:
| Items to check | Reasons to watch |
|---|---|
| Relationship with medical fees and nursing care fees | Is it income within the system? |
| Target of subsidies/additions | Will it be a tailwind in the initial stage of implementation |
| Track record of implementation in local governments, hospitals, and facilities | Isn't it just a demonstration? |
| Reducing on-site work time | Will it be evaluated as a countermeasure against labor shortage |
| Continuation rate after introduction | Will it be used even after the subsidy ends |
In the public insurance market, it is not only the sales growth rate that is important, but also whether the company will remain in the system.
Even if the number of introductions increases in the short term, the number of cancellations will not increase after the subsidy ends. On the other hand, services that are deeply integrated into the on-site business flow are more likely to remain in service for a long time, even if the price is lower.
US model｜In the private insurance market, “high unit price/performance fee type” is likely to grow
In the United States, there is a complex web of private insurance companies, Medicare, Medicaid, employers, and provider groups.
Price flexibility is higher than in Japan or Europe, and while excellent healthcare tech companies can easily secure contracts with high unit prices, insurance reimbursement and contracts with insurance companies are turning points for growth.
What is strong in the US-style market is technology that lowers payment costs for insurance companies and medical providers.
A typical example is
- Telemedicine
- Remote patient monitoring
- Chronic disease management app
- AI diagnosis support
- Mental health tech
- Home medical support
- Improved medication adherence
- Platform for preventing severe aggravation
These are the 8 areas.
CMS describes remote patient monitoring as a system in which patients collect health data, such as blood pressure, weight, and blood sugar, using connected devices and are managed remotely by health care providers. What we can see from this is that in the United States, ``data utilization to lower medical costs'' is likely to be the starting point for monetization.
The points investors should look at are:
| Items to check | Reasons to watch |
|---|---|
| Contract with major insurance company | Payer becomes clear |
| Compatible with Medicare/Medicaid | See possibilities for public reimbursement |
| Insurance reimbursement code | See reproducibility of sales |
| Revenue per patient | View unit economics |
| Retention rate/churn rate | Check if this is a temporary introduction |
| Clinical outcomes | See if it really reduces medical costs |
In the US healthcare tech industry, there are many companies that are in the red even though their sales are growing.
In that case, investors need to discern whether the company will become profitable if it scales up or whether the customer acquisition costs are too high and the company is structurally in the red.
Data regulations will determine the speed of growth of AI companies
The competitiveness of healthcare AI will largely depend on the quality and quantity of medical data.
However, medical data is some of the most sensitive personal information. Test values, diagnosis names, prescription history, nursing care records, genetic information, and mental health information have a large impact when leaked.
Therefore, data regulations will greatly affect the growth rate of healthcare AI companies.
| Region | Characteristics of data regulation | Investment perspective |
|---|---|---|
| Japan | Personal Information Protection Act, guidance for medical and nursing care providers | On-site implementation and safety management system are important |
| United States | Medical information protection centered on HIPAA | Covered entities and business associates are important |
| EU | GDPR and European Health Data Space | It's strict, but if broken, it becomes a barrier to entry |
| Emerging Asian countries | Each country is under development | Room for growth and risk of regulatory changes coexist |
Data regulation is more than just a cost.
Companies that can adapt to strict regulations will have an advantage over latecomers. This is because medical institutions and insurance companies are more likely to choose a company with a data management system that can withstand audits than a service that is only cheap.
In other words, regulatory responsiveness can be a moat for healthcare tech companies.
EU type | Strict regulations also act as a barrier to entry
The EU has strict personal information protection regulations such as GDPR. Furthermore, the European Health Data Space is becoming increasingly important as a framework for the use, sharing, and secondary use of health data within the EU.
This is a hurdle for healthcare AI companies.
However, precisely because the hurdles are so high, companies that break through have strengths.
Companies that can handle medical data in the EU are:
*Security
- Ethics
- Consent management
- Data governance
- Audit-ready
- Relationship of trust with medical institutions
It can be evaluated as having the following.
From an investor's point of view, when looking at companies operating in the EU, rather than looking at them in a short-sighted manner, thinking, ``It's not good because the regulations are too heavy,'' they should look at ``Can the regulations be used as a barrier to entry?''
Asia/North America type | Flexible data utilization is growing rapidly
In some North American and Asian markets, it is relatively easy to utilize medical data and introduce digital health.
In this case, AI learning data can be accumulated quickly and service improvements can be made faster. Telemedicine, online medical consultations, health management apps, insurance-linked wearables, etc. are themes that are likely to grow in this market.
However, the faster the growth of a market, the greater the risk of regulatory changes.
- Strengthening personal information protection
- Introduction of AI regulations
- Medical advertising regulations
- Cross-border data transfer regulations *Change in payment terms by insurance company
If this happens, the business model may suddenly change.
Investors would like to see a combination of growth speed and regulatory change risk.
Nursing care tech should be seen in combination with labor policy
In the nursing care tech market, not only the medical system but also labor policy is important.
How to solve the shortage of nursing care personnel differs from country to country.
| Solutions | Policies that are easy to introduce | Areas that are likely to grow |
|---|---|---|
| Compensating with people | Accepting immigrants, securing nursing care personnel | Staffing, education, facility management |
| Supplement with technology | Robot subsidies, ICT introduction support | Monitoring AI, nursing care record DX, transfer support |
| Move to home | Home medical care, community comprehensive care | Remote monitoring, medication management, home visit support SaaS |
In countries such as Japan and Scandinavia, where aging and labor shortages occur at the same time, policy support for nursing care robots, monitoring sensors, and nursing care record DX is likely to increase.
On the other hand, in countries where it is easy to fill the nursing care workforce with immigrants, the urgency to introduce robots and DX may be relatively low.
What is important when investing in nursing care technology is not just looking at the aging rate.
What is important is whether a country will solve its labor shortage with "people" or "technology."
Overseas expansion opportunities for Japanese companies
Japan is one of the world's most advanced countries with an aging population.
While this is a burden on the domestic market, it is also a demonstration market for medical DX and nursing care DX companies.
The systems for nursing care records, monitoring, home care, medication management, and medical data linkage that have been successful in Japan have the potential to be expanded to other countries in the future.
Compatibility is good with
- Korea *Taiwan
- Singapore *Germany
- Northern Europe
These areas are facing aging populations and labor shortages, and have relatively well-developed medical and nursing care systems.
However, overseas expansion is not easy.
Medical and nursing care needs to be adapted to local systems. Even models that are successful in Japan will stagnate if there are no language, legal regulations, data management, sales networks with medical institutions, insurance reimbursement, or local partners.
Diagram: Healthcare tech monetization route
Checklist for investors
When analyzing healthcare tech companies, look for:
| Check items | Points to see |
|---|---|
| Payer | Where does sales come from: the country, insurance companies, hospitals, nursing care facilities, and individuals? |
| Reimbursement status | Are medical fees, nursing care fees, insurance reimbursement, and subsidies supported |
| Implementation results | Are actual implementations increasing rather than demonstration experiments |
| Continuation rate | Is it being used even after the subsidy ends |
| ARPU | Will sales increase per facility, per patient, and per user |
| Gross profit margin | Is conversion to SaaS, data monetization, and maintenance monetization progressing? |
| Certification/Approval | Are medical device approvals, security certifications, and compliance with local laws |
| Data management | Can consent management, anonymous processing, cross-border transfer, and audit support be possible? |
| Sales cycle | Do you have the financial strength to absorb the length of sales to hospitals and local governments? |
| Overseas expansion | Are there sales, redemption, and legal systems that match local systems? |
This checklist will make it easier to see the difference between flashy theme stocks and companies that truly enter the system.
Indicators to look at in financial results and IR
It is difficult to judge medical DX/nursing care DX stocks based on sales alone.
In particular, you should look at:
| Indicators | Why investors watch |
|---|---|
| Sales by region | Which system areas are growing? |
| Payer Mix | Who Pays |
| Number of installed facilities | Check the speed of adoption |
| Sales per facility | View upsell potential |
| Churn rate | Check whether it has taken root in the field |
| Gross profit margin | See the progress of SaaS and standardization |
| Subsidy dependence | View system change risks |
| Research and development expenses | Look at regulatory compliance and sustainability of AI development |
| Operating cash flow | Look at the quality of profitability |
| Order backlog/contract period | View future sales forecast |
What I would like to pay particular attention to is the degree of subsidy dependence.
Subsidies serve as a catalyst for implementation. However, services that are canceled the moment the subsidy runs out are not strong enough.
Truly strong companies will use subsidies as an entry point to get involved in the on-site work flow and increase renewal rates and unit prices.
Characteristics of growing healthcare tech companies
Companies that are easy to grow have something in common.
- Anticipating system changes
- Deeply involved in practical work in medical and nursing care settings
- Compatible with insurance reimbursement and subsidies
- Clears data regulations
- High retention rate after introduction
- Able to adapt to local systems when expanding overseas
- AI and robots can be converted into “on-site cost reduction”
In other words, the competitiveness of healthcare tech is not just technological capabilities.
A company's strength as an investment target comes only when its ability to understand systems, on-site implementation ability, data management ability, sales network, and financial strength are combined.
Investment risk
Healthcare tech investments have their own risks.
| Risk | Contents |
|---|---|
| Delay in reimbursement | Delay in insurance coverage and medical fee reimbursement |
| Regulation changes | Rules for data use and medical advertising will change |
| Longer implementation cycle | Sales to hospitals and local governments takes time |
| Subsidy dependence | Termination of subsidy will increase cancellations |
| Not suitable for the site | Although convenient, it is not used because it increases the burden on site |
| Price control | Unit prices are slow to grow in the public insurance market |
| Lack of clinical evidence | Unable to prove effectiveness, preventing widespread use of contracts |
| Cybersecurity | Medical data leak damages trust |
Especially for healthcare tech companies that have just gone public, growth stories tend to take precedence.
It is not enough just to say that the number of facilities implementing the system is increasing. It is difficult to judge the actual corporate value without looking at the renewal rate, unit price, gross profit margin, and operating cash flow.
Investment decision conclusion
The important thing when investing in healthcare tech is not to jump at the word AI, DX, and robots.
What we really need to look at is who will buy the technology, how it will be paid, and whether it will become recurring revenue.
In the medical and nursing care fields, the speed of market expansion changes the moment something is incorporated into the legal system.
In the public insurance market, cost reduction and on-site burden reduction are important. In the US market, connections with insurance companies and Medicare/Medicaid are important. In the EU market, the barrier to entry is the ability to overcome strict data regulations. In nursing care technology, labor policies and countermeasures against labor shortages will be growth drivers.
Healthcare tech winners are not just companies with superior technology.
We are a company that can solve the puzzle of the complex medical and nursing care system and convert it into recurring revenue within the system.
By taking this perspective, it will be easier to find medical DX/nursing care DX stocks that will grow over the long term.
Source/Reference information
- Ministry of Health, Labor and Welfare, About medical DX
- Ministry of Health, Labor and Welfare, Promoting the use of nursing care technology
- Ministry of Health, Labor and Welfare, [Promoting the development and spread of nursing care robots] (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000209634.html)
- Centers for Medicare & Medicaid Services, Remote Patient Monitoring
- U.S. Department of Health & Human Services, Summary of the HIPAA Privacy Rule
- European Commission, European Health Data Space Regulation
- Personal Information Protection Commission, Personal Information Protection Act, etc.